Tablet formulation for ophthalmic disease prevention using a combination of lutein and naringin extracted from the flower of Tagetes erecta L. and fruit membrane of Citrus maxima (Burm.f.) Merr. extract

This study aimed to develop a dietary supplement tablet for the prevention of ophthalmic diseases using extracts from <i>Tagetes erecta</i> L. flowers and <i>Citrus maxima</i> (Burm.f.) Merr. fruit membranes. To enhance the extraction of lutein from <i>T. erecta</i> flowers and total phenolic compounds and naringin from <i>C. maxima</i> fruit membranes, a novel technique, enriched fraction column chromatography, was employed. The optimized tablet formulation comprised 350 mg of <i>T. erecta</i> flower extract, 300 mg of <i>C. maxima</i> fruit membrane extract, 200 mg of corn starch, 1 % aerosil, and 1.2 % magnesium stearate. Each tablet contains 7.7 mg of lutein and 20.8 mg of total phenolic compounds, meeting daily dietary requirements. The developed tablet's physical properties, both before and after stability testing, adhered to USP standards. This supplement holds promise for preventing ophthalmic diseases and other health conditions associated with lutein and phenolic compounds, such as cardiovascular diseases and cancer.